RxDoctor Payments Data

Realba Rodriguez Iglesias, MD

Internal Medicine · Bronx, NYNPI 1780978213

Payments from drug & device makers

$18,474in general payments, 2019–2025

Across 602 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • AstraZeneca$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Amgen$987
  • Astellas Pharma US Inc$814
  • plus $5K from 39 others

What the payments were for

  • Speaking & faculty fees$1,6009%
  • Food & beverage$16,56090%
  • Education$3142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,474 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$19,846
Medicare patients
35
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$94,495
Xigduo XrDapaglifloz Propaned/Metformin46$48,861
EliquisApixaban57$43,446
FarxigaDapagliflozin Propanediol24$38,358
LinzessLinaclotide35$36,366
Janumet XrSitagliptin Phos/Metformin Hcl25$29,917
JardianceEmpagliflozin27$28,600
JanuviaSitagliptin Phosphate22$27,767
JanumetSitagliptin Phos/Metformin Hcl23$16,451
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$16,382
XareltoRivaroxaban26$16,284
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$13,439
Tresiba Flextouch U-200Insulin Degludec16$12,649
Tresiba Flextouch U-100Insulin Degludec12$10,974
EntrestoSacubitril/Valsartan11$10,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$5,484$94,495104 claims
MerckJanumet Xr, Januvia, Janumet$452$74,13570 claims
PfizerEliquis$105$43,44657 claims
AstraZenecaFarxiga$1,714$38,35824 claims
AbbVieLinzess$750$36,36635 claims
Boehringer IngelheimJardiance$110$28,60027 claims
GSKTrelegy Ellipta$165$16,38227 claims
Johnson & JohnsonXarelto$22$16,28426 claims
NovartisEntresto$367$10,64811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →